In an attempt to design opioid-nociceptin hybrid peptides, three novel bivalent ligands, H-YGGFGGGRYYRIK-NH 2 , H-YGGFRYYRIK-NH 2 and Ac-RYYRIKGGGYGGFL-OH were synthesized and studied by biochemical, pharmacological, biophysical and molecular modelling tools. These chimeric molecules consist of YGGF sequence, a crucial motif in the N-terminus of natural opioid peptides, and Ac-RYYRIK-NH 2, which was isolated from a combinatorial peptide library as an antagonist or partial agonist that inhibits the biological activity of the endogenously occurring heptadecapeptide nociceptin. Solution structures for the peptides were studied by analysing their circular dichroism spectra. Receptor binding affinities were measured by equilibrium competition experiments using four highly selective radioligands. G-protein activating properties of the multitarget peptides were estimated in [
Introduction
G protein-coupled receptors (GPCRs) are ancestrally related membrane proteins on various cells that mediate the physiological and pharmacological effect of most drugs, hormones and neurotransmitters. GPCRs are the largest family of proteins encoded in the human genome. One of the most important types of GPCRs is the opioid receptors [1] [2] [3] [4] [5] [6] . Opioid family receptors consist of four closely related cell surface proteins expressed in all vertebrate animals examined to date. The three classical types of opioid receptors shown unequivocally to mediate analgesia in animal models and in humans are the mu-(MOP), delta-(DOP), and kappa-(KOP) opioid receptor proteins. The fourth and most recent member of the opioid receptor family described is the nociceptin or orphanin FQ receptor also called as NOP receptor or ORL-1 (opioid receptor like) receptor [7, 8] . The role of NOP receptor and its ligands in mediating analgesia is not as clear, with both analgesic and hyperalgesic effects reported.
Natural ligands for the opioid receptor subfamily are endogenous opioid peptides. They include Met-and Leu-enkephalin [9] , β-endorphin [10] , dynorphin A [11] and nociceptin or orphanin FQ [7, 8] . Opioid peptides are easy and frequent targets for chemical modifications, so it is not surprising that a huge amount of synthetic opioid peptides have been reported with various structural modifications for reviews see [12] [13] [14] and [15] [16] [17] [18] . Hybrid or bifunctional peptide or non-peptide ligands developed recently, bearing two pharmacophores, represent novel biochemical tools in investigating GPCRs and their interacting complexes. The pioneer synthetic bifunctional opioid peptide was a double enkephalin later named biphalin [19] . Biphalin (Tyr-DAla-Gly-Phe-NHeNH < − Phe < −Gly < − d-Ala < − Tyr) is an opioid octapeptide with a dimeric structure based on two identical pharmacophore portions, derived from enkephalins, joined "tail to tail" by a hydrazide bridge. Numerous structure-activity relationship studies (SAR) were performed in order to understand the elements responsible for the high activity of biphalin [20] . Beside biphalin, a number of other chimeric opioid peptides linked by spacer have been studied so far. Opioid peptides have often been combined with other bioactive neurotransmitters and peptide hormones that are involved in pain perception, e.g. substance P, neurotensin, cholecystokinin, cannabinoids, neuromedin ligands, etc. [21] . Such novel peptide chimeras (also called designed multiple ligands or twin or hybrid drugs), may interact independently with their respective receptor proteins.
Here we describe and characterize three novel hybrid opioid peptides using in vitro displacement binding and functional [ 35 S]GTPγS binding assay as well as mouse vas deferens bioassay. These bivalent ligands (BA55 and BA62) are composed either of the minimum opioid tetrapeptide structure (Tyr-Gly-Gly-Phe; YGGF) or (Tyr-Gly-Gly-PheLeu; YGGFL) targeting the opioid receptors, and a NOP receptor recognizing synthetic sequence Ac-Arg-Tyr-Tyr-Arg-Ile-Lys-NH 2 (Ac-RYYRIK-NH 2 ) isolated originally from combinatorial chemical libraries [22] . Ac-RYYRIK-NH 2 and its related hexapeptides were reported to behave as partial agonists [22] , therefore they are capable of antagonizing NOP receptor selective pure agonist ligands [23] [24] [25] [26] [27] . The related peptide fragments were either fused directly or connected via an arbitrary given short tripeptide spacer composed of three glycine residues (GGG). The structures of the three hybrid peptides are H-YG-GFGGGRYYRIK-NH 2 , H-YGGFRYYRIK-NH 2 , Ac-RYYRIKGGGYGGFL-OH. Combining the MOP/DOP/KOP receptor agonist structure with the NOP receptor partial agonist/antagonist sequence Ac-RYYRIK-NH 2 would result in effective bivalent compounds targeting the individual opioid receptors and perhaps their interacting complexes, e.g., MOP/ NOP or DOP/NOP receptor heterodimers.
Materials and methods

Chemicals
All amino acid derivatives, resins (Rink-amide MBHA, 2-chlorotrityl resin) and coupling agents were purchased from IRIS Biotech GmbH (Marktredwitz, Germany), Reanal (Budapest, Hungary) or Fluka (Buchs, Switzerland). Solvents for synthesis and HPLC were from Molar Chemicals (Budapest, Hungary) or Merck Kft (Budapest, Hungary). TrisHCl, MgCl 2 × 6H 2 O, EGTA, NaCl, GDP, the GTP analogue GTPγS, Bovine serum albumin (BSA), the [d-Ala2, d-Leu5] enkephalin (DADLE) and U-69,593 were purchased from Sigma-Aldrich (Budapest, Hungary). YGGF, Leu-enkephalin and nociceptin was obtained from Bachem Holding AG (Bubendorf, Switzerland). The Tyr-D-Ala-Gly-(NMe)Phe-Gly-ol (DAMGO), the Ile 
Circular dichroism (CD) spectroscopy
Far-UV CD spectra were recorded at 25°C temperature on Jasco J-810 spectropolarimeter on the peptide. The CD spectra were measured at between 260 and 185 nm with an optical pathlength of 1 mm, the peptide concentration was ∼ 0.1 mg/ml in Milli-Q water. The bandwidth was 2 nm and data pitch 1.0 nm, the scan speed was set to 100 nm/min and the integration time was 1 s. 10 spectra were accumulated and plotted. Far UV spectra were analized by CDSSTR method (dichroweb.cryst.bbk.ac.uk/html/home.shtml).
Near-UV range: Typical spectral accumulation parameters were the scanning speed 50 nm/min with 1 nm bandwidth and the 0.2 nm step resolution over wavelength range 240-325 nm with five scans averaged for each spectrum. The temperature at the cuvette was controlled by Peltier-type heating system. The raw ellipticity data were converted into molar ellipticity ([θ]/deg*cm 2*dmol − 1) for the near-UV region.
Molecular dynamics calculations
The conformers were generated by simulated annealing and energy minimization method. An initial unrestrained molecular dynamics simulation was performed at 1000 K to override the conformational barriers. The trajectory was sampled every picoseconds and the resulting snapshots were annealed to 50 K for two picoseconds and then energy minimized by RMS gradient convergence criterion of 0.001. Molecular modelling was performed by the Tinker program package v. 6.3.3 (Software Tools for Molecular Design Washington University Medical School, USA). All molecular dynamics steps were performed using the amber99 force field and GBSA implicit solvent environment. Investigation of the secondary structure of the conformers was performed by the Stride program [28] .
Animals
In experiments designed for receptor binding assay: male and female Wistar rats (250-300 g body weight) and male guinea pigs (∼700 g body weight, LAL/HA/BR strain) were used. Rats were housed in the local animal house of BRC (Szeged, Hungary), while guinea pigs were housed in LAB-ÁLL Bt. (Budapest, Hungary). For MVD experiments NMRI mice (35-45 g) were used. Mice were purchased from Toxicoop (Budapest, Hungary) and they were housed in the local animal house of the Department of Pharmacology and Pharmacotherapy, Semmelweis University (Budapest, Hungary) in group of 5 animals/ cage.
Animals were kept in a temperature controlled room (21-24°C) under a 12:12 light and dark cycle, allowed free access to tap water and standard rodent food until the time of sacrifice. The animals were handled humanely, in complete accordance with the European directive 2010/63/EU on the protection of animals used for scientific purposes and the Hungarian Act for the Protection of Animals in Research (XXVIII.tv. 32. §). Both the number of rats and their suffering were minimized throughout our experiments.
Peptide synthesis
The peptides were synthesized by solid phase peptide synthesis method using Fmoc strategy on Rink-amide MBHA (H-YGGFGGGRYYRIK-NH 2 , H-YGGFRYYRIK-NH 2 ) or on 2-chlorotrityl resin (Ac-RYYRIKGGGYGGFL-OH). Amino acids were coupled as Fmoc derivatives by the DIC/HOBt coupling method in DMF. After removal of the last Fmoc group, the N-terminus was acetylated by acetic anhydride and DIEA. The crude products were purified by semipreparative RP-HPLC and the purified compounds were characterized by analytical RP-HPLC and ESI-ion trap mass spectrometry.
2.6. Rat and guinea pig brain membrane homogenate preparation for binding assays Animals were decapitated and rat or guinea pig brains were quickly removed. The brains were prepared according to a method previously described [29] and partly used for binding experiments and partly were further prepared for the [ 35 S]GTPγS binding experiments according to [30] . Briefly, the full brain (without cerebellum) were homogenized, centrifuged in ice-cold 50 mM Tris-HCl (pH 7.4) buffer and incubated at 37°C for 30 min in a shaking water-bath for details see [31] . After incubation the centrifugation was repeated as described before and the final pellet was suspended in 50 mM ]Nociceptin the incubation mixture also contained 50 mM Tris/HCl, 2.5 mM EGTA, 5 mM MgCl 2 and 0.5 mg/ml fatty acid-free BSA (pH 7.4). The level of non-specific binding was determined in the presence of 10 mM unlabelled naloxone, U-69,593, nociceptin or naltrindole, while total binding was determined in the absence of cold compounds. The reaction was terminated by rapid filtration under vacuum (Brandel M24R Cell Harvester; Brandel Harvesters, Gaithersburg, MD), and washed three times with 5 ml ice-cold 50 mM Tris-HCl or 50 The experiments were performed in triplicates and repeated at least three times.
Mouse vas deferens (MVD) bioassay
Vasa deferentia from NMRI mice (35-45 g) were prepared as described previously [33] ). Briefly, vasa deferentia (a single organ/bath) were mounted between two electrodes under an initial tension 0.1 g in Mg 2+ free Krebs solution aerated with carbogen (O 2 :CO 2 = 95:5) at 31°C. Field electrical stimulation (upper ring, lower straight wire electrode arrangement) was used. The stimulation parameters were as follows: field stimulation, pairs (100 ms pulse distance) of rectangular impulses (1 ms pulse width, 9 V/cm i.e. supramaximal intensity) were repeated by 10 s. The muscle contractions were monitored by computer, using a data recording and analysis system (LabChart 5, ADInstruments Pty LTD, Australia).
Experimental paradigms of MVD
In the mouse vas deferens experiments, before adding the first dose of agonists, 30-40 min equilibration was used for tissues under stimulation. For all experiments, only one concentration-effect curve for the agonists was constructed per tissue [34] and each of these was constructed in cumulative manner. The drug exposure was less than 2 min, and the administration cycle 12-18 min. Preparations were then washed out and allowed to regain their pre-drug twitch height. Then they were equilibrated for 20 min with antagonists (naloxone, JTC-801, naltrindole, nor-BNI), and without washing a single concentration of agonist was added. To determine dissociation constants of the antagonist, dose ratio (DR) values were obtained by the single-dose method described [35] . 50 ) and the maximum Gprotein efficacy (E max ), respectively. For IC 50 and EC 50 values standard error is only given in their logarithm form by the curve fitting program due to the data representation. The specific binding of either radiolabelled compound was calculated by the subtraction of non-specific binding from total binding and was given in percentage. The data was normalized to total specific binding, which was settled 100%, which in case of [ 35 S]GTPγS also represents the basal activity of the G-protein.
Data analysis
In the MVD bioassay, the 50% effective concentration (EC 50 ) and maximal effect (Emax) was determined from the non-linear regression (Hill 4 parameters equation) of individual logarithmic concentration-response curves. The equilibrium dissociation constant of antagonists (K e ) was calculated with the single-dose method [35] . Antagonist affinities (K e values) were calculated as: K e = [antagonist concentration]/dose ratio −1. Experimental data were analysed and graphically represented as means ± S.E.M with curve fitting program, SigmaPlot 11.0. (Systat Software, San Jose, CA). Differences between two data sets unpaired ttest with two-tailed P-value statistical analysis was used, while for three or more data sets one-way ANOVA with Tukey's post hoc test was performed to determine statistical significance. Significance was accepted at the P < 0.05 level.
Results
Circular dichroism (CD) spectroscopy
Three novel hybrid peptides composed of opioid (YGGF) and nociceptin-like (RYYRIK) building blocks were synthesized and studied. A detailed analysis of the different ECD (electron-capture dissociation) spectra of the bivalent peptides provided the following structural information: Table within Fig. 1 . shows the relative distributions of secondary structures observed. Spectral data collected at 25°C were analysed by CDSSTR method using reference dataset: 3 [36] . Peptide BA55 has been associated with the unordered motive and the turns, while BA61 and BA62 the β-sheet and α-helix motives are dominant, respectively. Due to the aromatic amino acid content of these peptides the near-UV ECD region can also be informative (Fig. 1B, C and D) . All three peptides have similar spectral properties at all 3 temperatures recorded: i) a negative band at around 280 nm (L b of Tyr) disappearing at 85°C a bit more pronounced for BA61, ii) a positive band at about 260 nm (most probably L b of Phe) and iii) the shoulder of a larger band (248 nm) positive at 5°C reversed in sign at 85°C. In summary, the atypical far-UV ECD spectra, with bands strongly influenced by electronic transitions arising from the aromatic residues suggest rather an unstructured polypeptide main chain, which otherwise could have some partial order unrevealed at lower T, completely vanishing at elevated temperature.
Molecular dynamics calculations
The effect of the structure of the peptides on the biological activity on the NOP receptor was related to their secondary structure in solution analysed by both experimental and theoretical methods. Due to the conformational flexibility of peptides, a widely used experimental method to investigate their secondary structure is the electronic circular dichroism (CD) spectroscopy. In silico investigation of flexible peptides can be performed by the conformational analysis of conformer ensembles. Here we analysed ensembles of 50000 energy minimized conformers generated by molecular dynamics (MD) simulation (Fig. 2) . The binding activities shown for the NOP receptor can be correlated to the secondary structure patterns of the peptides. The amount of the turns present in the peptides seems to be proportional to the affinity, as in the most active BA61 turns were found in nearly 50%. Contrary to the turns, the presence of helices in the peptides showed a reverse effect, as the most helical BA62 proved to be inactive on NOP receptor. The percentile ratios and the location of the different secondary structure elements distributed within the conformer ensembles were compared to the experimental results obtained by CD. The percentage of a specific secondary structure was calculated as follows:
100x (sum of the affected resides in the ensemble)/(sum of all residues in the ensemble)
The negligible amount of beta strands in the conformers was in accordance of their absence in the CD spectra. The rank order of the overall amount of turns was the same as obtained by CD. In the case of helices, the helix content of the inactive BA62 was the highest, as expected. Besides the overall amount of the secondary structure elements their location was also investigated. The most abundant beta turn type IV distributed almost uniformly along the peptide chains. beta turn type I, the second highest amount turn type, mostly abounded close to the Nterminal in the most active BA61 but farther from the N-terminal in other two peptides (Figure turns) . The distribution of helices in the peptides seems to be related to the RYYRIK segment (Figure helices) . However, besides the core RYYRIK segment, the helical character seems to be prune to extend toward the nearby glycine rich regions too.
Receptor binding assays and functional [ 35 S]GTPγS binding experiments
Heterologous equilibrium competition curves are shown in Fig. 3 . and these studies are summarized in Table 1 . Each of the three peptides displaced the receptor type-selective radioligands with various affinities. The highest NOP receptor affinity was obtained with BA61 (K i 16 nM, Table 1) confirming that the Ac-RYYRIK-NH 2 N-terminal sequence carries NOP receptor interacting motifs. Most of the curves were accurately fitted by the 'one binding site' model. However, the curve for fit' calculation) . Moreover, the displacement curve of this competition was not complete (Fig. 3C panel) with substantial residual binding activity (around 50%). The apparent high affinities of H-YGGF-OH and BA61 in the KOP receptor assay (Fig. 3C panel) were also accompanied by higher residual binding levels.
Binding selectivity ratios were calculated as quotients of the corresponding K i values (Table 2) , while% relative affinity values (Table 2last column) were calculated according to [37] . BA55 is characterized by higher KOP/NOP receptor preference, although sequence predictions suggested rather a MOP/DOP receptor selectivity for BA55. BA61 peptide exhibits NOP receptor preference (75%), while the characteristic target for the peptide BA62 is the DOP receptor (66%).
Agonist induced and receptor mediated G-protein activation was studied by [ 35 S]GTPγS binding assays performed on rat or guinea pig brain membranes (Fig. 4) . All three bivalent peptide ligands effectively stimulated the activity of regulatory G-proteins in rat brain membranes with maximal stimulation levels of 149:126:149% for BA55:-BA61:BA62, respectively (Table 3) . On the basis of these E max values and those of Leu-enkephalin (H-YGGFL-OH), BA55 and BA62 are full agonists, while peptide BA61 seems to be a partial agonist ligand. In guinea pig brain membrane fractions, containing mainly KOP receptors, the stimulation order was BA55 ≈ BA62 > BA61, indicating again the partial agonist nature of BA61. The effects of the three hybrid peptides were also compared with those of the simple mixtures of their peptide building components. Thus, curves for the mixtures were substantially different from the curves depicting the real hybrid compounds (see Fig. 6 . depicts that the BA61, BA55, BA62 similarly to reference compounds inhibited the electrically-evoked MVD muscle contractions in concentration dependent manner. In MVD bioassay the EC 50 (nM) values were 160, 3860, 19400 for BA61, BA55, BA62, respectively (Table 4) . BA61 was lesser potent than any of the reference compounds but about 24-and 121-fold more potent than BA55 or BA62. The average E max was 100% for each compounds tested in the present work ( Table 4 (Table 4) . On the other side the naloxone (NX) K e values against BA55 and BA62 were 14.05 ± 2.7 (n = 5) and 3.8 ± 0.8 (n = 5) nM, respectively. The calculated K e value of NX against DAMGO (typical MOPr agonist) was 1.01 ± 0.14 (n = 3) and of JTC-801 against nociceptin (NOPr agonist) was 480 ± 72 (n = 3) nM.
Mouse vas deferens bioassay
Discussion
Different types of pain of moderate to severe intensity is often treated with opioid compounds with variable success. However, central and peripheral origin unwanted effects such as respiratory depression, constipation, tolerance and dependence are among main factors that limit the use of opiate therapy. One strategy to overcome the major side effects and to prolong the analgesic efficiency of the applied drugs Kosterlitz and Paterson (1980) . involves the creation of bi-or multifunctional compounds which contain hybridized structures [21, 38] . Combination of opioid agonist and antagonist pharmacophores in a single molecule has been considered and extensively investigated e.g. [39] , but opioids have also been combined with other bioactive neurotransmitters and peptide hormones that are involved in pain perception (e.g. neurotensin, neurokinins, such as substance P, cholecystokinin, cannabinoids, etc. [40] [41] [42] .
Three chimeric peptides were synthesized and studied in the current work. Amino acid sequence of the opioid peptide building blocks (YGGF) was selected according to the message-address model [43] ), while the composition of the other pharmacophore (RYYRIK) based on artificial hexapeptide sequences isolated from a combinatorial peptide library [22] . Ac-RYYRIK-NH 2 and Ac-RYYRIK-ol have been reported to display NOP receptor partial agonists with full antagonist properties in the presence of the pure agonist N/FQ [24] [25] [26] 44] . Combination of NOP receptor antagonists with MOP receptor agonists would be perspective as analgesics, although for that reason non-peptide structures could be optimal. Transmembrane helix II of the NOP receptor was shown to be involved in the recognition of the Ac-RYYRIK-NH 2 hexapeptide by photoaffinity labelling [45] while another molecular modelling and docking study described that both nociceptin and Ac-RYYRIK-NH 2 can able to activate NOP receptor and their receptor-bound conformations have similar 3D structures [46] .
Our novel peptide hybrids represent designed structures targeting at least two different GPCRs and perhaps their interacting complexes. Two peptides contain the YGGF opioid message motif at their N-terminus, and this region is followed by the C-terminally located Ac-RYYRIK-NH 2 hexapeptide sequence. The two pharmacophores were connected directly in BA62, or interconnected with a triglycine (GGG) spacer sequence in BA55. The third chimeric peptide ligand bears a Ac-RYYRIK-NH 2 sequence at the N-terminus, that was combined with the YGGF opioid receptor recognising motif or message sequence [43] via a triglycine (GGG) spacer. It is worth noting that, our peptide sequences are different from those reported by [47] . These authors described MOP/ NOP receptor hybrid peptides consisting of full or partial dermorphin sequences found originally in frog skin [48] ), fused with the Dooley's Ac-RYYRIK-NH 2 hexapeptide [47] .
Based on the different abundance in the peptides, the presence of turns close to the N-terminal may be important for the activity at NOP receptor. The presence of helices close to the N-terminal is contradictory. Due to its low percentage in BA61, the effect of helix on the affinity is presumably negligible and the RYYRIK segment is capable of exerting its effect. Comparing BA55 and BA62, despite they uniform Nterminal segment, the latter is inactive. This may be the consequence of helical segments close to N-termini, starting at Gly3. In addition, BA62 is the most abundant in helical segments according to CD spectra. In BA55, the helical segments are shifted from 3 residue away from the Nterminal, by the amount of the Gly-Gly-Gly spacer between the nociceptin fragment YGGF and RYYRIK. It seems that the helicity induced by Ac-RYYRIK-NH 2 less disturbed the structure of the N-terminal fragment in BA55 than did in BA62. Additionally, BA55 is less helical than BA62, according to CD.
In terms of binding affinity, the rank order of potency of the three peptides was BA61 > BA55 > BA62 at the KOP receptor. The good KOP receptor activity of BA55 and BA62 is not surprising, because the accumulation of positively charged amino acid side chains (two arginines and one lysine, R.R.K) at the opioid address domain is present in Fig. 6 . Concentration-response curves for the bivalent peptides and reference opioid compounds on the electrically evoked contractions of the mouse vas deferens. Data are presented as mean ± S.E.M. various prodynorphin-(PDYN) derived endogenous opioid peptides [49] , including dynorphin A 1-17 (RR…K.K), dynorphin B or rimorphin (RR.K⋯) and α-neo-endorphin (RK.K). These data are consistent with our hypothesis that appropriate modifications in the address domain of dynorphin analogues may affect efficacy. Our results confirm also the importance of the opioid "message" displayed by many opioid ligands but also suggest a potential role of receptor recognition and activation that may be mediated by EL2 through interactions with the "address" component of dynorphin-like peptides [50] . The good MOP and KOP receptor affinities of BA61 (Ac-RYYRIKGGGYGGF-OH) were not expected, because this peptide has no N-terminal tyrosine (Tyr, Y) at all, which is common in all endogenous opioid peptides, β-endorphin, enkephalins, dynorphins and neo-endorphins. Moreover, the original opioid message tetrapeptide is hidden at the C-terminus of BA61, so the C-terminal address region of this synthetic oligopeptide ligand has no positively charged amino acids important for the KOP-receptor recognition. The high KOP receptor affinity was not observed among the Dooley's hexapeptide analogues described earlier [24] [25] [26] [27] 51] . Peptides having the opioid message sequence YGGF at the N-terminus remained comparable full agonists with Leu-enkephalin (YGGFL) when their G-protein activating properties were studied in [ 35 (Fig. 3) . The E max (efficacy) values went up to 149, 149 and 184% for BA55, BA62 and Leu-enkephalin, respectively. The third peptide starting with Ac-RYYRIK-NH 2 sequence possesses partial agonist properties reaching an E max value of 126% (Table 3) . Ac-RYYRIK-NH 2 hexapeptides were consistently found to be partial agonists and/or antagonist ligands in a variety of biochemical and pharmacological assays [24] [25] [26] [27] 52] . It is also worthy to mention here that in the G-protein stimulation assays, simple mixtures composed from the parent peptide components of the hybridised ligands behaved differently when their effects were compared to the multitarget fused sequences bearing real chemical connections, i.e., covalent bonding. Ac-RYYRIK-NH 2 was able to inhibit the stimulation by Leu-enkephalin (Fig. 3B panel) , when it was present in the mixture, indicating that the Dooley's peptide has opioid antagonist activity in addition to the wellknown antagonism observed at the NOP receptors. In guinea pig brain membranes, where KOP receptors are predominant, BA55 (Fig. 3D  panel) and BA62 (Fig. 3F panel) mediated effects were additive by mixing them with the opioid tetrapeptide YGGF, the latter represents a minimum structure for opioid receptor activation [53] .
S]GTPγS binding experiments
BA55 and BA62 were significantly antagonized by the KOP receptor specific nor-binaltorphimine (nor-BNI) in the [
35 S]GTPγS binding experiments ( Fig. 4D and F panels), while BA61 was not affected by the addition of nor-BNI (Fig. 4E panel) . This phenomenon supports the KOP receptor preference of those hybrid peptides that contain the Nterminal opioid message sequence YGGF in the correct, N-terminally position. Interestingly enough, when the opioid tetrapeptide is located at the C terminus of the hybrid compound BA61, only nor-BNI was not able to antagonize the stimulation, while JTC-801, cyprodime and naltrindole produced significant inhibitions. For a comparison, we extended our study to examine the pharmacological properties of the test peptides in MVD, which hosting MOP, DOP, KOP and NOP receptors. The order of potency in this tissue was BA61 > BA55 > BA62. Applying different opioid receptor subtype antagonists revealed that, BA55 and BA62 showed non selective opioid receptor subtype mediated action (MOP, DOP and KOP receptor), whereas BA61 displayed affinity for DOP and NOP but not for KOP receptor. Based on the above mentioned data, the test peptides displayed potency order that matches what was determined in the binding assay. This similarity was also found in the action of BA55 and BA62 for KOP. In addition, the two peptides showed DOP receptor-mediated effect. However, the selectivity of these two peptides for DOP receptor was less that of DADLE, indicated by dissociation constants (Table 4) . The involvement of DOP and KOP receptor in the action of BA55 and BA62 is not surprising, since the two peptides have the same address and message domains. In contrast, BA61 has different N-terminal domain (Ac-R), and yet different C-terminal (carboxyl group). This observation is in good agreement with previous results, according to which the free carboxyl group containing enkephalins preferred DOP receptors [54, 55] . Moreover, keeping in mind that BA61 has N-terminal preferred by NOP receptor [24] [25] [26] 44] . Consequently, the observed pharmacological effect of this peptide might be stand on these changes. Indeed, we could not parallel measure the contribution of NOP and DOP receptor mediated by BA61, because MVD hosting all opioid receptor subtypes but the DOPr reserve is high [56, 57] . This tendency makes MVD very sensitive for DOP receptor mediated effect of BA61. Therefore, we measured the effect of JTC-801 against BA61 in the presence of NTI, a selective DOP receptor antagonist. Applying this strategy we could show the action of BA61 on NOP receptor.
Based on the different abundance in the peptides, the presence of turns close to the N-terminal may be important for the activity at NOP receptor. The presence of helices close to the N-terminal is contradictory. Due to its low percentage in BA61, the effect of helix on the affinity is presumably negligible and the Ac-RYYRIK segment is capable of exerting its effect. Comparing BA55 and BA62, despite their uniform N-terminal segment, the latter is inactive. This may be the consequence of helical segments close to N-termini, starting at Gly 3 . In addition, BA62 is the most abundant in helical segments according to CD spectra. In BA55, the helical segments are shifted from 3 residue away from the N-terminal, by the amount of the Gly-Gly-Gly spacer between the nociceptin fragment YGGF and RYYRIK. It seems that the helicity induced by RYYRIK disturbed less the structure of the N-terminal fragment in BA55 than did in BA62. Additionally, the location of the helices in BA55 is very similar to that in helix-constrained nociceptin analogues [58] (Fig. 2) allowing a nociceptin-like activation mechanism. A typical conformer of peptide BA55 having helical C-terminal tail is shown in Fig. 2C .
Summarizing the results we can tell that each of the three novel hybrid peptides carries either opioid-or NOP receptor interacting properties or both, as expected during the design. One of the original goal that was the combination of the natural opioid agonist tetrapeptide "message" region with the artificial NOP-receptor selective antagonist (RYYRIK) peptide sequence is fulfilled, although some of the data did not yield the desired specific result. On the other hand, fine selectivity for an individual receptor of the novel peptides was not expected, because these are targeting at least two receptor proteins. The resulting hybrid structures can at least partly served as bivalent compounds for receptor labelling. Our most important and surprising observation is that BA61 behaved as partial agonist at the opioid receptors notwithstanding there is no N-terminal opioid "message" sequence in its structure. Taken together, the tridecapeptide H-YGGFGGGRYYRIK-NH 2 (BA55) is moderately potent in the MVD bioassay, it exhibits a KOP/ NOP receptor preference, and it has mainly unordered conformations in solution. The shorter hybrid decapeptide composed of opioid message and NOP receptor/nociceptin address domains, H-YGGFRYYRIK-NH 2 (BA62), exhibited the weakest inhibition on the mouse vas deferens, it has more α-helix in its structure, and this chimeric peptide has been the most efficacious agonist in the G-protein stimulation assays. The third bivalent compound, the tetradecapeptide Ac-RYYRIKGGGYGGFL-OH (BA61) seems to be a quaint KOP receptor ligand, although its amino acid sequence is completely differing from those of the kappa-receptor selective endogenous opioid peptides. Bearing a NOP receptor recognising hexapeptide sequence, the high affinity of BA61 toward the NOP receptor has also been restored. Experiments on receptor co-expressing cell lines are in progress to examine the effects of these hybrid peptides on MOP-NOP receptor heterodimers.
